Study record

MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?

Yerra VG, Connelly KA · Cardiovasc Drugs Ther · 2025

ReviewSeveralEvidence tier R
PubMed 40172798doi:10.1007/s10557-025-07689-yCompare with another study

What this study reported

Commented editorially on MOTS-c in the context of diabetic cardiomyopathy. No abstract was available, so no measured outcomes could be extracted.

Limitations

Editorial with no abstract and no primary data; title-only annotation, so the content and any claims could not be verified.

Study record

Annotated fields for this study
Study modelReview
Substance studiedSeveralMore than one of these is central to the paper (common for reviews).
SpeciesNot reported
System studiedEditorial commentary on MOTS-c in diabetic cardiomyopathy
PopulationNot reported
DesignEditorial comment
Sample size as reportedNot reported
Control groupNot reported
Route (data field only)Not reported
Endpoints measurednot reported
Pathways measuredNot reported
Research areasCardiovascular · Metabolic
Evidence tierR — Review (context, not evidence)
Publication typesEditorial

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
n/a
Sample size
n/a
Controls
n/a
Outcome validity
n/a
Support for its own conclusion
n/a

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the title only, because no abstract is indexed.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.